5-HT2 receptor activation alleviates airway inflammation and structural remodeling in a chronic mouse asthma model. Flanagan, T., w., Sebastian, M., N., Battaglia, D., M., Foster, T., P., Cormier, S., A., & Nichols, C., D. Life sciences, 236:116790, 2019. Website abstract bibtex AIMS Although the bulk of research into the biology of serotonin 5-HT2A receptors has focused on its role in the CNS, selective activation of these receptors in peripheral tissues can produce profound anti-inflammatory effects. We previously demonstrated that the small molecule 5-HT2 receptor agonist (R)-2,5-dimethoxy-4-iodoamphetamine [(R)-DOI] inhibits TNF-α-mediated proinflammatory signaling cascades and inflammation via 5-HT2A receptor activation and prevents the development of, and inflammation associated with, acute allergic asthma in a mouse ovalbumin (OVA) model. Here, we investigated the ability of (R)-DOI to reverse inflammation and symptoms associated with established asthma in a newly developed model of chronic asthma. METHODS An 18-week ovalbumin challenge period was performed to generate persistent, chronic asthma in BALB/c mice. Four once daily intranasal treatments of (R)-DOI were administered one week after allergen cessation, with respiratory parameters being measured by whole-body plethysmography (WBP). Cytokine and chemokine levels were measured by quantitative real-time polymerase chain reaction (qRT-PCR) in homogenized lung tissue, bronchoalveolar (BALF) fluid was analyzed for chemokine modulation by multiplex assays, and Periodic Acid-Schiff and Masson's Trichrome staining was performed to determine goblet cell infiltration and overall changes to lung morphology. KEY FINDINGS 5-HT2 activation via (R)-DOI attenuates elevated airway hyperresponsiveness to methacholine, reduces pulmonary inflammation and mucus production, and reduces airway structural remodeling and collagen deposition by nearly 70%. SIGNIFICANCE Overall, these data provide support for the therapeutic potential of (R)-DOI and 5-HT2 receptor activation for the treatment of asthma, and identifies (R)-DOI as a novel therapeutic compound against pulmonary fibrosis.
@article{
title = {5-HT2 receptor activation alleviates airway inflammation and structural remodeling in a chronic mouse asthma model.},
type = {article},
year = {2019},
identifiers = {[object Object]},
pages = {116790},
volume = {236},
websites = {https://www.sciencedirect.com/science/article/abs/pii/S0024320519307179,http://www.ncbi.nlm.nih.gov/pubmed/31626791},
id = {fe53aca6-5bba-3de7-9d50-4cc70e01cda2},
created = {2019-11-01T19:15:29.089Z},
file_attached = {false},
profile_id = {38c6dbcb-2394-3f18-9217-58d777c08c69},
group_id = {d9389c6c-8ab5-3b8b-86ed-33db09ca0198},
last_modified = {2019-11-12T23:04:34.279Z},
tags = {CA,Disc:Pharmacology},
read = {false},
starred = {false},
authored = {false},
confirmed = {true},
hidden = {false},
notes = {TB},
private_publication = {false},
abstract = {AIMS Although the bulk of research into the biology of serotonin 5-HT2A receptors has focused on its role in the CNS, selective activation of these receptors in peripheral tissues can produce profound anti-inflammatory effects. We previously demonstrated that the small molecule 5-HT2 receptor agonist (R)-2,5-dimethoxy-4-iodoamphetamine [(R)-DOI] inhibits TNF-α-mediated proinflammatory signaling cascades and inflammation via 5-HT2A receptor activation and prevents the development of, and inflammation associated with, acute allergic asthma in a mouse ovalbumin (OVA) model. Here, we investigated the ability of (R)-DOI to reverse inflammation and symptoms associated with established asthma in a newly developed model of chronic asthma. METHODS An 18-week ovalbumin challenge period was performed to generate persistent, chronic asthma in BALB/c mice. Four once daily intranasal treatments of (R)-DOI were administered one week after allergen cessation, with respiratory parameters being measured by whole-body plethysmography (WBP). Cytokine and chemokine levels were measured by quantitative real-time polymerase chain reaction (qRT-PCR) in homogenized lung tissue, bronchoalveolar (BALF) fluid was analyzed for chemokine modulation by multiplex assays, and Periodic Acid-Schiff and Masson's Trichrome staining was performed to determine goblet cell infiltration and overall changes to lung morphology. KEY FINDINGS 5-HT2 activation via (R)-DOI attenuates elevated airway hyperresponsiveness to methacholine, reduces pulmonary inflammation and mucus production, and reduces airway structural remodeling and collagen deposition by nearly 70%. SIGNIFICANCE Overall, these data provide support for the therapeutic potential of (R)-DOI and 5-HT2 receptor activation for the treatment of asthma, and identifies (R)-DOI as a novel therapeutic compound against pulmonary fibrosis.},
bibtype = {article},
author = {Flanagan, Thomas w. and Sebastian, Melaine N. and Battaglia, Diana M. and Foster, Timothy P. and Cormier, Stephania A. and Nichols, Charles D.},
journal = {Life sciences}
}
Downloads: 0
{"_id":"5hBwsFHv7j8aTSE7v","bibbaseid":"flanagan-sebastian-battaglia-foster-cormier-nichols-5ht2receptoractivationalleviatesairwayinflammationandstructuralremodelinginachronicmouseasthmamodel-2019","authorIDs":[],"author_short":["Flanagan, T., w.","Sebastian, M., N.","Battaglia, D., M.","Foster, T., P.","Cormier, S., A.","Nichols, C., D."],"bibdata":{"title":"5-HT2 receptor activation alleviates airway inflammation and structural remodeling in a chronic mouse asthma model.","type":"article","year":"2019","identifiers":"[object Object]","pages":"116790","volume":"236","websites":"https://www.sciencedirect.com/science/article/abs/pii/S0024320519307179,http://www.ncbi.nlm.nih.gov/pubmed/31626791","id":"fe53aca6-5bba-3de7-9d50-4cc70e01cda2","created":"2019-11-01T19:15:29.089Z","file_attached":false,"profile_id":"38c6dbcb-2394-3f18-9217-58d777c08c69","group_id":"d9389c6c-8ab5-3b8b-86ed-33db09ca0198","last_modified":"2019-11-12T23:04:34.279Z","tags":"CA,Disc:Pharmacology","read":false,"starred":false,"authored":false,"confirmed":"true","hidden":false,"notes":"TB","private_publication":false,"abstract":"AIMS Although the bulk of research into the biology of serotonin 5-HT2A receptors has focused on its role in the CNS, selective activation of these receptors in peripheral tissues can produce profound anti-inflammatory effects. We previously demonstrated that the small molecule 5-HT2 receptor agonist (R)-2,5-dimethoxy-4-iodoamphetamine [(R)-DOI] inhibits TNF-α-mediated proinflammatory signaling cascades and inflammation via 5-HT2A receptor activation and prevents the development of, and inflammation associated with, acute allergic asthma in a mouse ovalbumin (OVA) model. Here, we investigated the ability of (R)-DOI to reverse inflammation and symptoms associated with established asthma in a newly developed model of chronic asthma. METHODS An 18-week ovalbumin challenge period was performed to generate persistent, chronic asthma in BALB/c mice. Four once daily intranasal treatments of (R)-DOI were administered one week after allergen cessation, with respiratory parameters being measured by whole-body plethysmography (WBP). Cytokine and chemokine levels were measured by quantitative real-time polymerase chain reaction (qRT-PCR) in homogenized lung tissue, bronchoalveolar (BALF) fluid was analyzed for chemokine modulation by multiplex assays, and Periodic Acid-Schiff and Masson's Trichrome staining was performed to determine goblet cell infiltration and overall changes to lung morphology. KEY FINDINGS 5-HT2 activation via (R)-DOI attenuates elevated airway hyperresponsiveness to methacholine, reduces pulmonary inflammation and mucus production, and reduces airway structural remodeling and collagen deposition by nearly 70%. SIGNIFICANCE Overall, these data provide support for the therapeutic potential of (R)-DOI and 5-HT2 receptor activation for the treatment of asthma, and identifies (R)-DOI as a novel therapeutic compound against pulmonary fibrosis.","bibtype":"article","author":"Flanagan, Thomas w. and Sebastian, Melaine N. and Battaglia, Diana M. and Foster, Timothy P. and Cormier, Stephania A. and Nichols, Charles D.","journal":"Life sciences","bibtex":"@article{\n title = {5-HT2 receptor activation alleviates airway inflammation and structural remodeling in a chronic mouse asthma model.},\n type = {article},\n year = {2019},\n identifiers = {[object Object]},\n pages = {116790},\n volume = {236},\n websites = {https://www.sciencedirect.com/science/article/abs/pii/S0024320519307179,http://www.ncbi.nlm.nih.gov/pubmed/31626791},\n id = {fe53aca6-5bba-3de7-9d50-4cc70e01cda2},\n created = {2019-11-01T19:15:29.089Z},\n file_attached = {false},\n profile_id = {38c6dbcb-2394-3f18-9217-58d777c08c69},\n group_id = {d9389c6c-8ab5-3b8b-86ed-33db09ca0198},\n last_modified = {2019-11-12T23:04:34.279Z},\n tags = {CA,Disc:Pharmacology},\n read = {false},\n starred = {false},\n authored = {false},\n confirmed = {true},\n hidden = {false},\n notes = {TB},\n private_publication = {false},\n abstract = {AIMS Although the bulk of research into the biology of serotonin 5-HT2A receptors has focused on its role in the CNS, selective activation of these receptors in peripheral tissues can produce profound anti-inflammatory effects. We previously demonstrated that the small molecule 5-HT2 receptor agonist (R)-2,5-dimethoxy-4-iodoamphetamine [(R)-DOI] inhibits TNF-α-mediated proinflammatory signaling cascades and inflammation via 5-HT2A receptor activation and prevents the development of, and inflammation associated with, acute allergic asthma in a mouse ovalbumin (OVA) model. Here, we investigated the ability of (R)-DOI to reverse inflammation and symptoms associated with established asthma in a newly developed model of chronic asthma. METHODS An 18-week ovalbumin challenge period was performed to generate persistent, chronic asthma in BALB/c mice. Four once daily intranasal treatments of (R)-DOI were administered one week after allergen cessation, with respiratory parameters being measured by whole-body plethysmography (WBP). Cytokine and chemokine levels were measured by quantitative real-time polymerase chain reaction (qRT-PCR) in homogenized lung tissue, bronchoalveolar (BALF) fluid was analyzed for chemokine modulation by multiplex assays, and Periodic Acid-Schiff and Masson's Trichrome staining was performed to determine goblet cell infiltration and overall changes to lung morphology. KEY FINDINGS 5-HT2 activation via (R)-DOI attenuates elevated airway hyperresponsiveness to methacholine, reduces pulmonary inflammation and mucus production, and reduces airway structural remodeling and collagen deposition by nearly 70%. SIGNIFICANCE Overall, these data provide support for the therapeutic potential of (R)-DOI and 5-HT2 receptor activation for the treatment of asthma, and identifies (R)-DOI as a novel therapeutic compound against pulmonary fibrosis.},\n bibtype = {article},\n author = {Flanagan, Thomas w. and Sebastian, Melaine N. and Battaglia, Diana M. and Foster, Timothy P. and Cormier, Stephania A. and Nichols, Charles D.},\n journal = {Life sciences}\n}","author_short":["Flanagan, T., w.","Sebastian, M., N.","Battaglia, D., M.","Foster, T., P.","Cormier, S., A.","Nichols, C., D."],"urls":{"Website":"https://www.sciencedirect.com/science/article/abs/pii/S0024320519307179,http://www.ncbi.nlm.nih.gov/pubmed/31626791"},"bibbaseid":"flanagan-sebastian-battaglia-foster-cormier-nichols-5ht2receptoractivationalleviatesairwayinflammationandstructuralremodelinginachronicmouseasthmamodel-2019","role":"author","downloads":0},"bibtype":"article","creationDate":"2019-12-02T17:57:03.029Z","downloads":0,"keywords":[],"search_terms":["ht2","receptor","activation","alleviates","airway","inflammation","structural","remodeling","chronic","mouse","asthma","model","flanagan","sebastian","battaglia","foster","cormier","nichols"],"title":"5-HT2 receptor activation alleviates airway inflammation and structural remodeling in a chronic mouse asthma model.","year":2019}